Hepatitis E virus Infections and Infestations Other acute viral hepatitis
Conditions
Interventions
Routine tests:
The following tests will be taken at baseline as this is routinely done at Patan Hospital:
1. Haematology: full blood count including white blood differential counts, reticulocytes, pla
measured weekly until they normalise
4.2. Random blood glucose, as clinically indicated
4.3. Creatinine, sodium/potassium
weekly or as clinically indicated
4.4. Serology: hepatitis A immunoglobulins G and M (HepA IgG/M), hepatitis B surface antigen (HBsAg), anti-HBs and anti-core, hepatitis C IgG and hepatitis E IgG/M at
an abdominal ultrasound scan will be performed routinely for all patients to assess gestational age, liver texture, ascites, etc on admission and to obstetric demand
Tests for research study:
1. Vira
Sponsors
University of Oxford (UK)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. All pregnant women aged greater than or equal to 15 years presenting to Patan Hospital with elevated liver enzymes and/or jaundice will be invited to participate in the study (100 patients) 2. All non-pregnant women aged greater than or equal to 15 years presenting to Patan Hospital with elevated liver enzymes and/or jaundice will be invited to participate in the study (100 patients) 3. Informed written consent
Exclusion criteria
Exclusion criteria: 1. No consent 2. Other co-morbidities: chronic liver disease, chronic renal disease, cardiac disease 3. Alcohol abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical, virological and immunological features of HEV infection in pregnant women in Patan Hospital will be studied, with particular reference to maternal and neonatal morbidity and mortality (in the pregnant patients only): 1. Mechanism of inducing high morbidity and mortality in pregnancy 2. Maternal death 3. The rate of preterm labour 4. Stillbirth 5. Intrauterine foetal death 6. Neonatal death 7. Post-partum haemorrhage 8. Rate of vertical transmission | — |
Secondary
| Measure | Time frame |
|---|---|
| We will be studying and recording the following outcomes in the pregnant and non-pregnant group: 1. Proportion of patients infected with HEV 2. Proportion of patients developing fulminant hepatitis in the two groups 3. Death 4. Correlation between viral loads, liver enzymes, liver activity scores, T-cell counts and clinical outcome 5. The route of infection in pregnant and non-pregnant women using GPS mapping and epidemiological data | — |
Countries
Nepal
Outcome results
None listed